Back

Sacubitril/valsartan treatment: effect on left ventricular remodelling and fibrosis assessed by novel heart failure biomarkers

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Heart failure pharmacotherapy - Sacubitril/valsartan Ventricular Remodelling ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mrs Ainhoa Robles Mezcua

Virgin of Victory University Hospital, Malaga (Spain)

7 More presentations in this session

Presentation thumbnail
Haemodynamic forces as predictors of cardiac remodelling and outcome in heart failure with reduced ejection fraction treated with sacubitril/valsartan
Assistant Professor A. Giannoni (Pisa, IT)
Abstract Slides
Presentation thumbnail
Maximum dose sacubitril/valsartan in heart failure with reduced ejection fraction: does atrial fibrillation compromise the benefits?
Doctor G. Oliveira Campos (Coimbra, PT)
Abstract Slides
Presentation thumbnail
Efficacy and safety of sacubitril valsartan in heart failure compared to renin angiotensin aldosterone system inhibitors: a systematic review and meta analysis of randomised controlled trials
Professor A. Bielecka-Dabrowa (Lodz, PL)
Abstract Slides
Presentation thumbnail
Effects of sacubitril valsartan on renal function in adults with heart failure: a systematic review and meta analysis of randomised controlled trials
Professor A. Hernandez (Storrs, US)
Abstract Slides
Presentation thumbnail
Heart failure with improved ejection fraction (HFimpEF) in patients treated with sacubitril/valsartan (SV)
Assistant Professor K. Lee (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Heart failure pharmacotherapy - Sacubitril/valsartan

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Left ventricular reverse remodeling in heart failure with reduced ejection fraction: determinants and outcomes in a multidisciplinary heart failure clinic in a resource limited setting
thumbnail
Congress Presentation
New paradigms in pathological mechanosensing

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources